Sign in
4

Changes in Ownership

Alkermes plc. Filed Acc 0001127602-22-006332

EVP R&D, Chief Medical Officer sold 2,306 shares at $25.17 ($58,042)

  • EVP R&D, Chief Medical Officer gave up 8,527 shares (to pay taxes)
  • EVP R&D, Chief Medical Officer acquired 29,008 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-18 Sale −2,306 $25.17 $58,042 9,496 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-20 Option exercise +10,096 19,592 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-20 Shares withheld for taxes −2,966 $25.08 $74,387 16,626 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-21 Option exercise +6,875 23,501 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-21 Shares withheld for taxes −2,022 $25.08 $50,712 21,479 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-22 Option exercise +12,037 33,516 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-22 Shares withheld for taxes −3,539 $25.01 $88,510 29,977 D
Derivatives
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-18 Grant or award · Employee Stock Option (Right to Buy) +139,554 139,554 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-18 Grant or award · Restricted Stock Unit Award +34,889 34,889 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-20 Option exercise · Restricted Stock Unit Award −10,096 20,191 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-21 Option exercise · Restricted Stock Unit Award −6,875 6,875 D
Hopkinson Craig C. EVP R&D, Chief Medical Officer 2022-02-22 Option exercise · Restricted Stock Unit Award −12,037 36,114 D
Open-market sales · 2,306 sh · avg $25.17 · $58,042
Loading xslF345X03/form4.xml…